IL170807A - Use of 4-hydroxy tamoxifen for the preparation of a medicament containing a penetration enhancer isopropyl myristate for percutaneous administration for treatment of breast cancer - Google Patents

Use of 4-hydroxy tamoxifen for the preparation of a medicament containing a penetration enhancer isopropyl myristate for percutaneous administration for treatment of breast cancer

Info

Publication number
IL170807A
IL170807A IL170807A IL17080705A IL170807A IL 170807 A IL170807 A IL 170807A IL 170807 A IL170807 A IL 170807A IL 17080705 A IL17080705 A IL 17080705A IL 170807 A IL170807 A IL 170807A
Authority
IL
Israel
Prior art keywords
hydroxy tamoxifen
tamoxifen
breast
weight
hydroxy
Prior art date
Application number
IL170807A
Other languages
English (en)
Hebrew (he)
Original Assignee
Besins Healthcare Lu Sarl
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Lu Sarl, Besins Int Lab filed Critical Besins Healthcare Lu Sarl
Publication of IL170807A publication Critical patent/IL170807A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL170807A 2003-04-01 2005-09-12 Use of 4-hydroxy tamoxifen for the preparation of a medicament containing a penetration enhancer isopropyl myristate for percutaneous administration for treatment of breast cancer IL170807A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
IL170807A true IL170807A (en) 2014-08-31

Family

ID=33131847

Family Applications (1)

Application Number Title Priority Date Filing Date
IL170807A IL170807A (en) 2003-04-01 2005-09-12 Use of 4-hydroxy tamoxifen for the preparation of a medicament containing a penetration enhancer isopropyl myristate for percutaneous administration for treatment of breast cancer

Country Status (11)

Country Link
US (2) US7704516B2 (enExample)
EP (3) EP1608353B1 (enExample)
JP (1) JP5490346B2 (enExample)
AU (1) AU2003294973B2 (enExample)
CA (1) CA2519980C (enExample)
ES (3) ES2483896T3 (enExample)
IL (1) IL170807A (enExample)
MX (1) MXPA05010597A (enExample)
NO (1) NO333805B1 (enExample)
NZ (1) NZ542499A (enExample)
WO (1) WO2004087123A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327363D1 (de) * 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
WO2004087123A1 (en) * 2003-04-01 2004-10-14 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
ES2304610T3 (es) * 2003-06-09 2008-10-16 Ascend Therapeutics, Inc. Tratamiento y prevencion de cicatrizacion excesiva con 4-hidroxi-tamoxifeno.
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
MXPA06010914A (es) * 2004-03-22 2006-12-15 Besins Int Lab Tratamiento y prevencion de enfermedades de mama benigna con 4-hidroxi tamoxifen.
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
GEP20104889B (en) * 2004-10-14 2010-02-10 Laboratoires Besins Int 4-hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
EP3143392B1 (en) * 2014-05-12 2023-02-22 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen metabolites by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
EP3230478B1 (en) * 2014-12-12 2023-08-02 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
CA3022377A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies
US12201591B2 (en) 2019-07-03 2025-01-21 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
WO2025019830A1 (en) * 2023-07-19 2025-01-23 Atossa Therapeutics, Inc. Anti-tumor compounds and methods of use thereof and synthesis thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
EP0287690B1 (de) * 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (enExample) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
ATE200978T1 (de) 1996-03-29 2001-05-15 S W Patentverwertungs Ges M B KOSMETIKUM BZW. KOSMETIKZUSAMMENSETZUNG ZUR GLÄTTUNG UND STRAFFUNG DER HAUT BEI GESTÖRTEM UNTERHAUT-BINDE-FETTGEWEBE, INSBESONDERE BEI DER ßCELLULITEß
JP2001527037A (ja) 1997-12-23 2001-12-25 ヘキサル アーゲー Ｚ−４−ヒドロキシタモキシフェン及びシクロデキストリンを含む混合物及び薬剤学的組成
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
ATE290856T1 (de) 1999-12-16 2005-04-15 Dermatrends Inc Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
PT1317921E (pt) 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
WO2004087123A1 (en) 2003-04-01 2004-10-14 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
ES2304610T3 (es) 2003-06-09 2008-10-16 Ascend Therapeutics, Inc. Tratamiento y prevencion de cicatrizacion excesiva con 4-hidroxi-tamoxifeno.
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
US7704516B2 (en) 2010-04-27
EP1608353B1 (en) 2014-04-30
US20090186944A1 (en) 2009-07-23
EP1952810A1 (en) 2008-08-06
MXPA05010597A (es) 2006-03-09
HK1119950A1 (en) 2009-03-20
AU2003294973B2 (en) 2010-05-13
US20050031695A1 (en) 2005-02-10
EP1608353A1 (en) 2005-12-28
JP2006514967A (ja) 2006-05-18
EP1941871B1 (en) 2014-01-08
AU2003294973A1 (en) 2004-10-25
CA2519980C (en) 2012-04-10
HK1086193A1 (en) 2006-09-15
EP1952810B1 (en) 2014-01-08
NZ542499A (en) 2008-10-31
NO333805B1 (no) 2013-09-16
US8475814B2 (en) 2013-07-02
ES2456958T3 (es) 2014-04-24
ES2456957T3 (es) 2014-04-24
CA2519980A1 (en) 2004-10-14
WO2004087123A1 (en) 2004-10-14
NO20054526L (no) 2005-09-30
EP1941871A1 (en) 2008-07-09
JP5490346B2 (ja) 2014-05-14
ES2483896T3 (es) 2014-08-08

Similar Documents

Publication Publication Date Title
US8475814B2 (en) Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US8048927B2 (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1572171B1 (en) Reduction of breast density with 4-hydroxy tamoxifen
EP1579856A1 (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
AU2005227072B2 (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
HK1119950B (en) Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
HK1086193B (en) Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
HK1079453A (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
HK1077512B (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1077512A1 (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1096595B (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
HK1130435A (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1120228A (en) Formulations for the reduction of breast density with 4-hydroxy tamoxifen
HK1130435B (en) Reduction of breast density with 4-hydroxy tamoxifen

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed